<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596293</url>
  </required_header>
  <id_info>
    <org_study_id>BBT401-UC-005</org_study_id>
    <nct_id>NCT04596293</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study of Orally Administered BBT-401-1S in Subjects With Moderate to Severe Ulcerative Colitis, Incorporating a Response-adaptive, Double-blind Extension Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bridge Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bridge Biotherapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, placebo-controlled, proof of clinical principle study to&#xD;
      explore the efficacy and safety of orally administered BBT-401-1S in subjects with ulcerative&#xD;
      colitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response rate</measure>
    <time_frame>Week 8</time_frame>
    <description>Measured by a reduction of ≥3 points and ≥30% improvement from baseline of total Mayo score, which includes a decrease in rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore ≤1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission rate</measure>
    <time_frame>Week 8</time_frame>
    <description>Measured by a total Mayo score of ≤2 points, with no individual subscore exceeding 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission rate</measure>
    <time_frame>Week 8</time_frame>
    <description>Measured by a Mayo endoscopic subscore of 0 or 1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>BBT-401-1S (800mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BBT-401-1S (1,600mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBT-401-1S</intervention_name>
    <description>BBT-401-1S 8 weeks + Extension phase 8 weeks</description>
    <arm_group_label>BBT-401-1S (1,600mg)</arm_group_label>
    <arm_group_label>BBT-401-1S (800mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 8 weeks + Extension phase 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, of any race, ≥18 and ≤60 years of age.&#xD;
&#xD;
          -  Have been diagnosed with active UC for ≥3 months prior to Day 1, as determined by&#xD;
             clinical and endoscopic evidence and documented in a histopathology evaluation.&#xD;
&#xD;
          -  Have a total Mayo score ≥6, an endoscopic subscore ≥2, rectal bleeding subscore ≥1,&#xD;
             and a stool frequency subscore ≥1, regardless of standard of care history.&#xD;
&#xD;
          -  Able to comprehend and willing to voluntarily sign an ICF and to abide by the study&#xD;
             restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received:&#xD;
&#xD;
               1. intravenous corticosteroids, rectally administered corticosteroids, or rectally&#xD;
                  administered 5-aminosalicylic acid within 3 weeks, or&#xD;
&#xD;
               2. Janus kinase (JAK) inhibitors within 2 weeks, or&#xD;
&#xD;
               3. cyclosporine, mycophenolate, tacrolimus, or methotrexate within 5 weeks, or&#xD;
&#xD;
               4. anti-TNF-α biologics within 9 weeks, or&#xD;
&#xD;
               5. any other biologics (including ustekinumab and vedolizumab) for the treatment of&#xD;
                  UC within 12 weeks.&#xD;
&#xD;
          -  Have received orally administered azathioprine or 6-mercaptopurine that has been&#xD;
             stable for &lt;8 weeks. Doses of oral drugs must remain stable until the last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Have received orally administered 5-aminosalicylic acid, sulphasalazine, or low-dose&#xD;
             corticosteroids (prednisolone ≤20 mg/day or equivalent) that have been stable for &lt;5&#xD;
             weeks. Doses of oral drugs must remain stable until the last dose of study drug.&#xD;
&#xD;
          -  Have received any other concomitant medications for UC that have been stable (ie, have&#xD;
             not started dosing with a new drug or had a change to their dosing regimen) for &lt;7&#xD;
             days or 5 half-lives, whichever is longer.&#xD;
&#xD;
          -  Have Crohn's disease, indeterminate colitis, ischaemic colitis, fulminant colitis,&#xD;
             toxic megacolon, chronic (as determined by the investigator) pancolitis, confined&#xD;
             proctitis (distal, ≤15 cm), or symptomatic intestinal stenosis.&#xD;
&#xD;
          -  Have a history of extensive colonic resection (subtotal or total colectomy) or are&#xD;
             anticipated to require surgical intervention for UC.&#xD;
&#xD;
          -  Have an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.&#xD;
&#xD;
          -  Have a positive test for Clostridium difficile, or have evidence of treatment for&#xD;
             Clostridium difficile infection or other pathogenic bowel infection within 60 days or&#xD;
             for another intestinal pathogen within 30 days prior to Day 1.&#xD;
&#xD;
          -  Have active infection with the human immunodeficiency virus or hepatitis B or C&#xD;
             viruses.&#xD;
&#xD;
          -  Have clinically significant active extraintestinal infection (eg, pneumonia,&#xD;
             pyelonephritis).&#xD;
&#xD;
          -  Have, in the opinion of the investigator, clinically significant abnormal vital signs,&#xD;
             physical examination findings, or 12-lead electrocardiograms (ECGs) at screening or&#xD;
             Day 1.&#xD;
&#xD;
          -  Have a history of any disease or condition (including mental and emotional conditions)&#xD;
             that, in the opinion of the investigator (or designee), would affect participation in&#xD;
             this study.&#xD;
&#xD;
          -  Have clinically significant abnormal liver function tests, including:&#xD;
&#xD;
               1. estimated glomerular filtration rate ≤50 mL/min/1.73m2&#xD;
&#xD;
               2. alanine aminotransferase or aspartate aminotransferase &gt;2 × the upper limit of&#xD;
                  normal (ULN)&#xD;
&#xD;
               3. direct bilirubin &gt;1.5 ULN.&#xD;
&#xD;
          -  Have other clinically significant abnormal clinical laboratory results that, in the&#xD;
             opinion of the investigator, preclude participation in the study, including:&#xD;
&#xD;
               1. platelet count &lt;100,000/μL&#xD;
&#xD;
               2. haemoglobin &lt;8.5 g/dL&#xD;
&#xD;
               3. neutrophils &lt;1500/μL&#xD;
&#xD;
               4. lymphocytes &lt;500/mm3&#xD;
&#xD;
               5. absolute white blood cells count &lt;3000/μL.&#xD;
&#xD;
          -  Have participated in a clinical study involving administration of an investigational&#xD;
             drug in the past 30 days prior to Day 1.&#xD;
&#xD;
          -  Have previously participated in any study of BBT-401-1S.&#xD;
&#xD;
          -  In the opinion of the investigator (or designee) or the sponsor, should not&#xD;
             participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bridge Biotherapeutics, Inc.</last_name>
    <phone>+82-31-8092-3280</phone>
    <email>clinicaltrials.gov_inquiries@Bridgebiorx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Premier Gastroenterology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Paul Svoboda, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastro Care Institute</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kumaravel Perumalsamy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Javara Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Ferris, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research</name>
      <address>
        <city>Riverton</city>
        <state>Utah</state>
        <zip>84065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kent Smith, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Haeundae</city>
        <state>Busan Gwang'yeogsi</state>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-Oh Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Bugok</city>
        <state>Daegu</state>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SeongWoo Jeon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wŏnju</city>
        <state>Gang'weondo</state>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Soo Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gwang'yeogsi</state>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ByungIk Jang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggido</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ja-Seol Koo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic university of Korea, Seoul St Mary's Hospital</name>
      <address>
        <city>Seocho</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Seok Cho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research Ltd., Suite 11, Promed House,</name>
      <address>
        <city>Tauranga</city>
        <state>Bay Of Plenty</state>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Stubbs, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research Wellington Ltd.</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Stubbs, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie,</state>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Wisniewska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Melita Medical</name>
      <address>
        <city>Wrocław</city>
        <state>Wroclaw</state>
        <zip>50-449</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslaw Leszczyszyn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny Nr. 1 im. Norberta Barlickiego</name>
      <address>
        <city>Łódź</city>
        <state>Łódzkie</state>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Malecka-Wojciesko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VITA LONGA Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <state>Śląskie</state>
        <zip>40-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemyslaw Ramos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise City Clinical Hospital No. 2 named after prof. O.O. Shalimov of the</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivs'ka Oblast</state>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olena Datsenko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise Kherson City Clinical Hospital named after E.E.Karabelesha of Kherso</name>
      <address>
        <city>Kherson</city>
        <state>Khersons'ka Oblast</state>
        <zip>73003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Malytska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Centre of the Limited Liability Company Medical Clinic Blagomed, Treatment and Diagnostic Di</name>
      <address>
        <city>Kyiv</city>
        <state>Kyïv</state>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mykhailo Pugach, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit enterprise Kyiv City Clinical Hospital No. 18, of the executive body of the Kyiv</name>
      <address>
        <city>Kyiv</city>
        <state>Kyïv</state>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetiana Kravchenko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center RCLIN Ukraine of the Limited Liability Company Cardiocom</name>
      <address>
        <city>Obukhiv</city>
        <state>Kyïv</state>
        <zip>08711</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetiana Nechypurenko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Enterprise Volyn Regional Clinical Hospital of the Volyn Regional Council, Department of S</name>
      <address>
        <city>Luts'k</city>
        <state>Vinnyts'ka Oblast</state>
        <zip>43005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmytro Shulga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center of LLC Oxford Medical-Vinnytsia</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnyts'ka Oblast</state>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliia Kizlova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit enterprise Vinnytsya city clinical hospital 1 gastroenterology department</name>
      <address>
        <city>Vinnytsya</city>
        <state>Vinnyts'ka Oblast</state>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halyna Tomashkevych, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise of the Kyiv Regional Council Kyiv Regional Hospital, Therapeutics De</name>
      <address>
        <city>Kyiv</city>
        <zip>04078</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetiana Logdanidi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

